Matthew Davis is a Neurology physician. ClinicalTrials.gov lists 19 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1000 State Route 35 Ste 101
Middletown, NJ 077482609
Telephone
732-629-9699Provider last certified this registry record 26 Oct 2023.
Clinical trials
- Milciclib in Combination With Gemcitabine in Advanced NSCLC
Sponsor: Tiziana Life Sciences LTD
- Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis
Sponsor: Par Pharmaceutical, Inc.
- Panblok H7 Vaccine Adjuvanted With AS03 or MF59
Sponsor: Biomedical Advanced Research and Development Authority
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
43 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year202548 payments$64,647openpaymentsdata.cms.gov ↗
- Avadel CNS Pharmaceuticals, LLCProgram year202543 payments$34,638openpaymentsdata.cms.gov ↗
- HARMONY BIOSCIENCES LLCProgram year202523 payments$29,159openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
99.1%Gabapentinoids18.6%Gabapentin76%Pregabalin13%Horizant12%Part D<11 patientsNonergot Dopamine Agonist9.3%Pramipexole Dihydrochloride57%Neupro32%Ropinirole Hcl11%Part D<11 patients+ 24 more classes in this area
Respiratory
0.9%Opium alkaloids and derivatives0.9%Ascomp With Codeine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”